William Blair analyst Brandon Vazquez has maintained their bullish stance on ENOV stock, giving a Buy rating today.
Brandon Vazquez has given his Buy rating due to a combination of factors that indicate a promising growth trajectory for Enovis. The company’s sales and profitability align with expectations, and the guidance for 2025 suggests further improvements in revenue growth and margin expansion. This positive outlook is supported by the company’s current valuation, which is attractive at just nine times the projected 2025 EBITDA, and the successful integration of previous acquisitions, which minimizes potential headwinds.
Enovis’s growth prospects are further bolstered by the introduction of new products, including a recently launched shoulder product and an upcoming hip system, which are expected to drive share gains. Additionally, the anticipated international launch of the Arvis system in 2025 could open new markets, particularly those that are cost-sensitive but still seek advanced technology. With a clear path to margin expansion through an increasing reconstruction mix and core operating leverage, Vazquez views Enovis’s risk/reward profile as favorable, positioning it as a durable low-double-digit profitability compounder.
In another report released today, Needham also reiterated a Buy rating on the stock with a $64.00 price target.